[Ala20]-beta-Amyloid (1-42)

[Ala20]-beta-Amyloid (1-42) is a modified form of the amyloid-beta peptide with an alanine substitution at position 20, affecting its aggregation properties. The peptide plays a central role in Alzheimer's disease by forming plaques in the brain. Researchers use this analog to study the effects of sequence modifications on amyloid aggregation, plaque formation, and toxicity in Alzheimer's research.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.

CAT No: A13291

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.

Featured Services
Epitope Mapping ServicesPeptide Analysis ServicesCustom Conjugation ServicePeptide Modification ServicesPeptide Nucleic Acids SynthesisPeptide CDMOPeptide Synthesis ServicescGMP Peptide Service
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers

We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy

x